Edwards Lifesciences Corp — Director's Dealing 2021

Oct 18, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edwards Lifesciences Corp (EW)
CIK: 0001099800
Period of Report: 2021-10-18

Reporting Person: Szyman Catherine M. (CVP, Critical Care)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-18	Common Stock	M	9741.0000	$21.7600	Acquired	37155.5223	Direct
2021-10-18	Common Stock	S	2603.0000	$110.8715	Disposed	34552.5223	Direct
2021-10-18	Common Stock	S	7138.0000	$110.2386	Disposed	27414.5223	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-18	Employee Stock Option (Right to Acquire)	$21.7600	M	9741.0000	Disposed	2022-05-13	Common Stock (9741.0000)	Direct

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021.

F2: This transaction was executed in multiple trades at prices ranging from $110.6400 to $110.9100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

F3: This transaction was executed in multiple trades at prices ranging from $109.6400 to $110.6100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.